Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Blood (2020) 136 (25): 2851–2863.

https://doi.org/10.1182/blood.2020008553

Published: 2020

Includes: Supplemental data

Journal Articles

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Stephanie Sasse, MD, Jesko Momotow, MD, Annette Plütschow, Andreas Hüttmann, MD, Nadezda Basara, MD, Christian Koenecke, MD, Sonja Martin, MD, Martin Bentz, MD, Christina Grosse-Thie, MD, Sven Thorspecken, MD, Maike de Wit, MD, Carsten Kobe, MD, Markus Dietlein, MD, Bastian von Tresckow, MD, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141250

Published: 2020

Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138413

Published: 2020

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe, MD, Hans Eich, MD, Christian Baues, MD, Richard Greil, MD, Stephanie Sasse, MD, Josée M Zijlstra, MD, Andreas Lohri, MD, Andreas Rosenwald, Bastian von Tresckow, MD, Volker Diehl, MD, Georg Kuhnert, Markus Dietlein, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2018) 132 (Supplement 1): 925.

https://doi.org/10.1182/blood-2018-99-114519

Published: 2018

Journal Articles

Balancing risk and benefit in early-stage classical Hodgkin lymphoma

Paul J. Bröckelmann, Stephanie Sasse, Andreas Engert

Blood (2018) 131 (15): 1666–1678.

https://doi.org/10.1182/blood-2017-10-772665

Published: 2018

Journal Articles

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Blood (2017) 130 (Supplement 1): 1450.

https://doi.org/10.1182/blood.V130.Suppl_1.1450.1450

Published: 2017

Journal Articles

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Stefanie Kreissl, MD, Bastian von Tresckow, MD, Helen Goergen, PhD, Heinz Haverkamp, Stephanie Sasse, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2016) 128 (22): 923.

https://doi.org/10.1182/blood.V128.22.923.923

Published: 2016

Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert

Blood (2015) 125 (26): 4024–4031.

https://doi.org/10.1182/blood-2014-12-614636

Published: 2015

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

Journal Articles

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Achim Rothe, MD, Stephanie Sasse, MD, Max S. Topp, MD, Dennis A. Eichenauer, MD, Bastian von Tresckow, MD, Horst-Dieter Hummel, MD, Miroslav Ravic, MD PhD, Jens-Peter Marschner, MD, Andreas Engert, MD

Blood (2014) 124 (21): 1753.

https://doi.org/10.1182/blood.V124.21.1753.1753

Published: 2014

Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Blood (2014) 123 (11): 1658–1664.

https://doi.org/10.1182/blood-2013-07-512657

Published: 2014

Includes: Supplemental data

Journal Articles

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Bastian von Tresckow, MD, Helen Görgen, Annette Plütschow, PhD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Achim Rothe, MD, Michael Fuchs, MD, Karolin Behringer, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2013) 122 (21): 4231.

https://doi.org/10.1182/blood.V122.21.4231.4231

Published: 2013

Journal Articles

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Bastian von Tresckow, MD, Heinz Haverkamp, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2013) 122 (21): 637.

https://doi.org/10.1182/blood.V122.21.637.637

Published: 2013

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Achim Rothe, MD, Stephanie Sasse, MD, Helen Goergen, Dennis A. Eichenauer, MD, Andreas Lohri, MD, Ulrich Jäger, Christopher Bangard, Andreas Engert, MD

Blood (2012) 120 (21): 2743.

https://doi.org/10.1182/blood.V120.21.2743.2743

Published: 2012

Journal Articles

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Stephanie Sasse, MD, Magdalena Alram, Medical Student, Horst Mueller, PhD, Lenka Smardova, MD, Bernd Metzner, Hartmut Döhner, MD, Thomas Fischer, MD, Vladan Vucinic, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, John M. Raemaekers, MD, PhD, Oliver Schmalz, MD, Bastian von Tresckow, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 552.

https://doi.org/10.1182/blood.V120.21.552.552

Published: 2012

Journal Articles

Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience

Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, Michael von Bergwelt Baildon, Sebastian Theurich, Peter Borchmann, Andreas Engert

Blood (2012) 120 (7): 1470–1472.

https://doi.org/10.1182/blood-2012-05-430918

Published: 2012

NARROW

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Balancing risk and benefit in early-stage classical Hodgkin lymphoma

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only